MBOT, US59503A2042

Microbot Medical stock has a negative price-to-earnings ratio of -3.64

Published on 10/17/2026 at 20:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market capitalization stood at USD 63.8 million on October 16, 2026. Microbot Medical stock was USD 0.95 on Nasdaq.

Valuation and market position

The negative price-to-earnings ratio was -3.64 on October 16, 2026.
Market capitalization stood at USD 63.8 million on October 16, 2026.
Microbot Medical stock was last at USD 0.95 on October 16, 2026 at 4:00 p.m. ET on Nasdaq.

MBOT, US59503A2042, Illustration mit AI erstellt.

Microbot Medical had a negative price-to-earnings ratio of -3.64 as of October 16, 2026, while its market capitalization stood at USD 63.8 million. Microbot Medical was last at USD 0.95 on October 16, 2026 at 4:00 p.m. ET on Nasdaq.

Valuation remains the key figure

The negative price-to-earnings ratio reflects the companys loss-making position rather than a conventional earnings multiple. Microbot Medical reported a net loss attributable to common shareholders of USD 5.63 million in the second quarter of 2026, compared with USD 3.67 million in the first quarter, according to the companys investor-relations release.

Revenue was USD 241,000 in the second quarter of 2026, up from USD 105,000 in the first quarter. The comparison shows a larger operating scale than at the start of the year, but the quarterly loss remained the dominant valuation factor.

Microbot Medical develops robotic devices

Microbot Medical operates in medical devices and develops robotic instruments for endoluminal surgery. Its LIBERTY system is designed for endovascular procedures, while the company also maintains development programs for other micro-robotic technologies.

On October 6, 2026, Microbot Medical entered a three-year exclusive distribution agreement for Israel with Medtechnica Ltd., according to Microbot Medical. The agreement adds a commercial distribution channel, while future revenue contribution remains dependent on adoption and procedures.

Comparison with peers

Microbot Medical: price-to-earnings ratio -3.64, market capitalization USD 63.8 million
Intuitive Surgical (Nasdaq, USD): price-to-earnings ratio 48.54, market capitalization USD 150.7 billion
Envista Holdings (NYSE, USD): price-to-earnings ratio 39.48, market capitalization USD 3.7 billion

Price and market context

The Nasdaq listing gives Microbot Medical access to a much larger medical-device market than its current valuation suggests, but the company remains substantially smaller than both comparison companies. Its next reported quarterly date has not been formally established in the cited company material.

Microbot Medicals latest reported quarterly revenue of USD 241,000 and net loss of USD 5.63 million were dated to the second quarter of 2026. The first-quarter comparison was USD 105,000 of revenue and a USD 3.67 million net loss.

Microbot Medical was last at USD 0.95 on Nasdaq on October 16, 2026 at 4:00 p.m. ET.